Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review

Cancer Letters

Volumn 379, Issue 1, 2016, Pages 100-106

  Shah, Dimpy P ^a   Shah, Pankil K ^a   Azzi, Jacques M ^a   El Chaer, Firas ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; HMPV; Leukemia; Lymphoma; Mortality; Stem cell transplantation

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTIFICIAL VENTILATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN METAPNEUMOVIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION RATE; LOWER RESPIRATORY TRACT INFECTION; MORTALITY RATE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT SURVEY; SYSTEMATIC REVIEW; VIRUS CULTURE; VIRUS LOAD; ADVERSE EFFECTS; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; METAPNEUMOVIRUS; MORTALITY; PARAMYXOVIRIDAE INFECTIONS; PATHOGENICITY; PREDICTIVE VALUE; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; RISK FACTOR; VIROLOGY;

ANTIVIRAL AGENTS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS;

EID: 84975516000     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.05.035     Document Type: Review

References (50)

1. Williams J.V., Martino R., Rabella N., Otegui M., Parody R., Heck J.M., et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J. Infect. Dis 2005, 192:1061-1065.
2. Peck A.J., Englund J.A., Kuypers J., Guthrie K.A., Corey L., Morrow R., et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007, 110:1681-1688.
3. Renaud C., Campbell A.P. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr. Opin. Infect. Dis 2011, 24:333-343.
4. Englund J.A., Boeckh M., Kuypers J., Nichols W.G., Hackman R.C., Morrow R.A., et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann. Intern. Med 2006, 144:344-349.
5. Wyde P.R., Chetty S.N., Jewell A.M., Boivin G., Piedra P.A. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003, 60:51-59.
6. Hamelin M.E., Prince G.A., Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob. Agents Chemother 2006, 50:774-777.
7. Muller A., Kupfer B., Vehreschild J., Cornely O., Kaiser R., Seifert H., et al. Fatal pneumonia associated with human metapneumovirus (HMPV) in a patient with myeloid leukemia and adenocarcinoma in the lung. Eur. J. Med. Res 2007, 12:183-184.
8. Pelletier G., Déry P., Abed Y., Boivin G. Respiratory tract reinfections by the new human metapneumovirus in an immunocompromised child. Emerg. Infect. Dis 2002, 8:976-978.
9. Cane P.A., van den Hoogen B.G., Chakrabarti S., Fegan C.D., Osterhaus A.D.M.E. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant 2003, 31:309-310.
10. Huck B., Egger M., Bertz H., Peyerl-Hoffman G., Kern W.V., Neumann-Haefelin D., et al. Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. J. Clin. Microbiol 2006, 44:2300-2303.
11. Kamble R.T., Bollard C., Demmler G., LaSala P.R., Carrum G. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant 2007, 40:699-700.
12. Abed Y., Boivin G. Human metapneumovirus infection in immunocompromised child. Emerg. Infect. Dis 2008, 14:854-856.
13. Bonney D., Razali H., Turner A., Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin: correspondence. Br. J. Haematol 2009, 145:667-669.
14. Shahda S., Carlos W.G., Kiel P.J., Khan B.A., Hage C.A. The human metapneumovirus: a case series and review of the literature. Transpl. Infect. Dis 2011, 13:324-328.
15. Shachor-Meyouhas Y., Ben-Barak A., Kassis I. Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (HMPV) in immune compromised child. Pediatr. Blood Cancer 2011, 57:350-351.
16. van Dijk N.M., Linssen C.F.M., Bussink M., Span L.F.R., van Mook W.N.K.A. Critical illness after horizontal nosocomial transmission of human metapneumovirus in the haematology ward. Neth. J. Crit. Care 2012, 16:22-25.
17. Kamboj M., Gerbin M., Huang C.-K., Brennan C., Stiles J., Balashov S., et al. Clinical characterization of human metapneumovirus infection among patients with cancer. J. Infect 2008, 57:464-471.
18. Campbell A.P., Chien J.W., Kuypers J., Englund J.A., Wald A., Guthrie K.A., et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J. Infect. Dis 2010, 201:1404-1413.
19. Hofmeyr A., Dunlop L., Ling S., Fiakos E., Maley M. Ribavirin treatment for human metapneumovirus and methicillin-resistant Staphylococcus aureus co-infection in adult haematological malignancy. Clin. Microbiol. Infect 2011, 17:S812.
20. Lee J.H., Jang J.H., Yoo K.H., Sung K.W., Koo H.H., Lee N.Y., et al. Incidence, clinical features, and outcome of respiratory virus infections in paediatric patients after haematopoietic stem cell transplantation. Bone Marrow Transplant 2011, 46:S228.
21. Fazekas T., Eickhoff P., Rauch M., Verdianz M., Attarbaschi A., Dworzak M., et al. Prevalence and clinical course of viral upper respiratory tract infections in immunocompromised pediatric patients with malignancies or after hematopoietic stem cell transplantation. J. Pediatr. Hematol. Oncol 2012, 34:442-449.
22. Srinivasan A., Gu Z.M., Smith T., Morgenstern M., Sunkara A., Kang G.L., et al. Prospective detection of respiratory pathogens in symptomatic children with cancer. Pediatr. Infect. Dis. J. 2013, 32:E99-E104.
23. Choi J.H., Choi E.H., Kang H.J., Park K.D., Park S.S., Shin H.Y., et al. Respiratory viral infections after hematopoietic stem cell transplantation in children. J. Korean Med. Sci 2013, 28:36-41.
24. Martino R., Porras R.P., Rabella N., Williams J.V., Ramila E., Margall N., et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol. Blood Marrow Transplant 2005, 11:781-796.
25. Debiaggi M., Canducci F., Terulla C., Sampaolo M., Marinozzi M.C., Alessandrino P.E., et al. Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. New Microbiol 2007, 30:255-258.
26. Souza J.S., Watanabe A., Carraro E., Granato C., Bellei N. Severe metapneumovirus infections among immunocompetent and immunocompromised patients admitted to hospital with respiratory infection. J. Med. Virol 2013, 85:530-536.
27. Debur M.C., Vidal L.R., Stroparo E., Nogueira M.B., Almeida S.M., Takahashi G.A., et al. Human metapneumovirus infection in hematopoietic stem cell transplant recipients. Transpl. Infect. Dis 2010, 12:173-179.
28. Wolfromm A., Porcher R., Legoff J., Peffault de Latour R., Xhaard A., Ribaud P., et al. Viral respiratory infections after allogeneic hematopoietic stem cell transplantation: outcome and prognosis. Biol. Blood Marrow Transplant 2014, 20:1238-1241.
29. Oliveira R.R., Machado A.F., Tateno A.F., Boas L.S.V., Pannuti C.S., Machado C.M. Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years. Bone Marrow Transplant 2008, 42:265-269.
30. Mikulska M., Del Bono V., Dini S., Raiola A., Dominietto A., Bregante S., et al. Respiratory viral infections after allogeneic haematopoietic stem cell transplantation. Clin. Microbiol. Infect 2011, 17:S615.
31. Chebotkevich V. The challenge of respiratory viral infections in onco-haematological patients. Clin. Microbiol. Infect 2010, 16:S705.
32. Kwon J.C., Cho S.Y., Kim S.H., Park S.H., Choi S.M., Lee D.G., et al. Microbiology from bronchoscopy in haematologic patients: comparison of stem cell recipients with nonrecipients. Clin. Microbiol. Infect 2012, 18:616.
33. Park S.Y., Baek S., Lee S.O., Choi S.H., Kim Y.S., Woo J.H., et al. Efficacy of oral ribavirin in hematologic disease patients with paramyxovirus infection: analytic strategy using propensity scores. Antimicrob. Agents Chemother 2013, 57:983-989.
34. Seo S., Gooley T.A., Kuypers J.M., Stednick Z., Jerome K.R., Englund J.A., et al. Human metapneumovirus infections following Hematopoietic Cell Transplantation: factors associated with disease progression. Clin. Infect. Dis 2016, 10.1093/cid/ciw284.
35. El Chaer F., Shah D.P., Kmeid J., Ariza-Heredia E., Hosing C., Chemaly R.F. Human metapneumovirus (hMPV) infections in 135 cancer patients 2015, IDWeek; San Diego, California.
36. Muller A., Klinkenberg D., Vehreschild J., Cornely O., Tillmann R.L., Franzen C., et al. Low prevalence of human metapneumovirus and human bocavirus in adult immunocompromised high risk patients suspected to suffer from Pneumocystis pneumonia. J. Infect 2009, 58:227-231.
37. Godet C., Le Goff J., Beby-Defaux A., Robin M., Raffoux E., Arnulf B., et al. Human metapneumovirus pneumonia in patients with hematological malignancies. J. Clin. Virol 2014, 61:593-596.
38. Span L.F.R., van Dijk N.M., Linssen C.F.M., van Mook W.N.K.A. Human metapneumovirus in immunocompromised patients with haematological malignancies: awareness with caution and respect!. Bone Marrow Transplant 2009, 43:S59.
39. Egli A., Bucher C., Dumoulin A., Stern M., Buser A., Bubendorf L., et al. Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation. Infection 2012, 40:677-684.
40. Renaud C., Xie H., Seo S., Kuypers J., Cent A., Corey L., et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol. Blood Marrow Transplant 2013, 19:1220-1226.
41. Ali M., Baker J., Richardson S.E., Weitzman S., Allen U., Abla O. Human metapneumovirus infection in children with cancer. J. Pediatr. Hematol. Oncol 2013, 35:444-446.
42. Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant 2008, 41:707-708.
43. Hirsch H.H., Martino R., Ward K.N., Boeckh M., Einsele H., Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin. Infect. Dis 2013, 56:258-266.
44. Tzannou I., Nicholas S., Misra A., Katari U., Orange J., Vera J., et al. Adoptive T-cell therapy to prevent and treat human metapneumovirus (hMPV) infections post hematopoietic stem cell transplant (HSCT) BMT tandem meeting. Biol. Blood Marrow Transplant 2015, 21:S170.
45. Hamelin M.E., Couture C., Sackett M., Kiener P., Suzich J., Ulbrandt N., et al. The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. Antivir. Ther 2008, 13:39-46.
46. Ulbrandt N.D., Ji H., Patel N.K., Riggs J.M., Brewah Y.A., Ready S., et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J. Virol 2006, 80:7799-7806.
47. Williams J.V., Chen Z., Cseke G., Wright D.W., Keefer C.J., Tollefson S.J., et al. A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. J. Virol 2007, 81:8315-8324.
48. Hamelin M.E., Gagnon C., Prince G.A., Kiener P., Suzich J., Ulbrandt N., et al. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Res 2010, 88:31-37.
49. Lévy C., Aerts L., Hamelin M., Granier C., Szécsi J., Lavillette D., et al. Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. Vaccine 2013, 31:2778-2785.
50. Debiaggi M., Canducci F., Sampaolo M., Marinozzi M.C., Parea M., Terulla C., et al. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J. Infect. Dis 2006, 194:474-478.